Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: Barbara L. Dallap x
  • Refine by Access: Content accessible to me x
Clear All Modify Search
in Journal of the American Veterinary Medical Association

Abstract

Objective—To determine the pharmacokinetics and pharmacodynamics of ϵ-aminocaproic acid (EACA), including the effects of EACA on coagulation and fibrinolysis in healthy horses.

Animals—6 adult horses.

Procedures—Each horse received 3.5 mg of EACA/kg/min for 20 minutes, IV. Plasma EACA concentration was measured before (time 0), during, and after infusion. Coagulation variables and plasma α2-antiplasmin activity were evaluated at time 0 and 4 hours after infusion; viscoelastic properties of clot formation were assessed at time 0 and 0.5, 1, and 4 hours after infusion. Plasma concentration versus time data were evaluated by use of a pharmacokinetic analysis computer program.

Results—Drug disposition was best described by a 2-compartment model with a rapid distribution phase, an elimination half-life of 2.3 hours, and mean residence time of 2.5 ± 0.5 hours. Peak plasma EACA concentration was 462.9 ± 70.1 μg/mL; after the end of the infusion, EACA concentration remained greater than the proposed therapeutic concentration (130 μg/mL) for 1 hour. Compared with findings at 0 minutes, EACA administration resulted in no significant change in plasma α2-antiplasmin activity at 1 or 4 hours after infusion. Thirty minutes after infusion, platelet function was significantly different from that at time 0 and 1 and 4 hours after infusion. The continuous rate infusion that would maintain proposed therapeutic plasma concentrations of EACA was predicted (ie, 3.5 mg/kg/min for 15 minutes, then 0.25 mg/kg/min).

Conclusions and Clinical Relevance—Results suggest that EACA has potential clinical use in horses for which improved clot maintenance is desired.

Full access
in American Journal of Veterinary Research
in Journal of the American Veterinary Medical Association